IntoCell Inc is a Korea-based company principally engaged in the development of antibody-drug conjugate (ADC) platform technology. The Company mainly develops ortho-hydroxy-protected aryl sulfate (OHPAS) platform technology, which is a linker connecting to drugs. In addition, the Company also develops platform technologies such as payload modification technology (PMT) platform technology, which reduces drug uptake into normal cells, and proprietary drug technology used in ADC development.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
14/26/14	₩16,270.00	-3.56%	31,190
11/26/11	₩16,870.00	-0.65%	21,644
10/26/10	₩16,980.00	-1.34%	31,277
09/26/09	₩17,210.00	-1.77%	25,257
08/26/08	₩17,520.00	+0.98%	39,029

End-of-day quote Korea S.E.

More quotes

Annual profits - Rate of surprise

Company calendar

End-of-day quote Korea S.E. 14/09/2026			5-day change	1st Jan Change
16,270.00 ^KRW	-3.56%		-6.22%	-71.66%

23/07	Samsung EpiS Unit Signs Cancer Drug Development, Commercialization Deal with IntoCell	MT
22/12	IntoCell, Inc.(KOSDAQ:A287840) added to S&P Global BMI Index	CI

Market Cap	24TCr 18Cr 16Cr 15Cr 13Cr 25Cr 1.74TCr 25Cr 177.2Cr 68Cr 882.25Cr 68Cr 67Cr 2.8TCr	P/E 2024 *	-	P/E 2025	-77.1x
Enterprise Value	22TCr 17Cr 14Cr 14Cr 12Cr 23Cr 1.59TCr 23Cr 162.28Cr 63Cr 807.94Cr 62Cr 61Cr 2.57TCr	EV / Sales 2024 *	-	EV / Sales 2025	36,55,59,272x
Free-Float	78.73%	Yield 2024 *	-	Yield 2025	-

23/07	Samsung EpiS Unit Signs Cancer Drug Development, Commercialization Deal with IntoCell	MT
22/12	IntoCell, Inc.(KOSDAQ:A287840) added to S&P Global BMI Index	CI
31/25/31	IntoCell Inc. and Xcellon Biologics Announce MOU to Expand Access to Next-Generation ADC Technologies	CI
30/25/30	Piramal Pharma Solutions Formalizes Partnership with IntoCell, Expanding Its Payload-Linker Platform and Bioconjugate Capabilities	CI

1 day	-3.56%
1 week	-6.22%
Current month	-14.19%
1 month	-26.88%
3 months	-27.20%
6 months	-66.21%
Current year	-71.66%

IntoCell, Inc. Share Price

Stocks

A287840

KR7287840003

Biotechnology & Medical Research

Valuation: IntoCell, Inc.

Chart: IntoCell, Inc.

Latest news: IntoCell, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: IntoCell, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

1 week	16,130	17,950
1 month	16,130	22,925
Current year	13,050	63,500
1 year	13,050	74,900
3 years	13,050	74,900
5 years	13,050	74,900
10 years	13,050	74,900

Manager	Title	Age	Since
Tae-Kyo Park CEO	Chief Executive Officer	66	01/04/2015
Young-Seok Seo DFI	Director of Finance/CFO	69	01/06/2019
Yo-Seop Yu CTO	Chief Tech/Sci/R&D Officer	58	01/04/2021

Director	Title	Age	Since
Tae-Kyo Park BRD	Director/Board Member	66	01/04/2015
Yo-Seop Yu BRD	Director/Board Member	58	01/04/2021
Gyeong-Se Min BRD	Director/Board Member	65	01/04/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.	Importance
15/07/25	Tae-Kyo Park	Buy	Founder	10,000	0.0674%
15/07/25	Tae-Kyo Park	Buy	Founder	26,000	0.1751%
28/05/25	Jae-Hee Choi	Free		40,400	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INTOCELL, INC.	-3.56%	-6.22%	-57.85%	-	19Cr
LONZA GROUP AG	+0.56%	-4.71%	-2.45%	+9.18%	4.55TCr
REVOLUTION MEDICINES, INC.	+0.66%	-2.34%	+340.62%	+530.14%	4.37TCr
IQVIA HOLDINGS INC.	+1.49%	-0.78%	+41.90%	+24.75%	4.31TCr
BEONE MEDICINES AG	+2.11%	-1.24%	+9.09%	+78.25%	3.94TCr
CELLTRION, INC.	+0.34%	-4.03%	+9.34%	+38.90%	3.19TCr
ASCENDIS PHARMA A/S	+0.53%	-2.08%	-	-	1.73TCr
MEDPACE HOLDINGS, INC.	+1.34%	+0.70%	+21.35%	+112.62%	1.64TCr
EUROFINS SCIENTIFIC SE	+2.07%	+0.78%	+13.07%	+30.91%	1.42TCr
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.85%	-5.33%	+78.63%	+31.45%	1.33TCr
Average	+0.37%	-2.89%	+50.41%	+107.03%	2.65TCr
Weighted average by Cap.	+0.94%	-2.83%	+75.90%	+127.96%

	2024	2025
Net sales	2.91T 2.16 1.87 1.76 1.6 3 206.71 3.02 21.06 8.12 104.86 8.1 7.92 333.38	2.3T 1.71 1.48 1.4 1.27 2.38 163.6 2.39 16.67 6.42 82.99 6.41 6.27 263.85
Net income	-991.28Cr -73.59L -63.77L -60.18L -54.59L -1.02Cr -71Cr -1.03Cr -7.19Cr -2.77Cr -36Cr -2.76Cr -2.7Cr -113.76Cr	-1.06TCr -78.72L -68.21L -64.37L -58.4L -1.1Cr -75Cr -1.1Cr -7.69Cr -2.96Cr -38Cr -2.96Cr -2.89Cr -121.69Cr
Net Debt	-214.59Cr -15.93L -13.8L -13.03L -11.82L -22.17L -15Cr -22.33L -1.56Cr -59.95L -7.75Cr -59.84L -58.52L -25Cr	-2.06TCr -1.53Cr -1.32Cr -1.25Cr -1.13Cr -2.13Cr -146.48Cr -2.14Cr -15Cr -5.75Cr -74Cr -5.74Cr -5.61Cr -236.25Cr